Hydroxychloroquine is used to treat patients with systemic lupus erythematosus and their dosage

Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by inflammation of various organs and is closely associated
with the innate and adaptive immune systems.

After HCQ was approved for SLE therapy in Japan in July 2015, many patients with SLE who received immunosuppressants began to be treated with HCQ
.

SLEDAI scores of patients with SLE who are treated with conventional or low-dose HCQ at baseline, 3-month follow-up, and 6-month follow-up:

Methods: Disease activity was
assessed using SELENA-SLEDAI 2011 standard, cutaneous lupus erythematosus disease area and severity index (CLASI), and serum biomarkers.

Results: 61 patients with
SLE who received HCQ and did not receive additional immunosuppressive therapy for more than 3 months were enrolled.

The magnitude of change in SLEDAI score (A), CLASI activity score (B), and serum immunobiomarker level (CF) in SLE patients receiving conventional or low-dose HCQ therapy 6 months after initiation of HCQ therapy:

In summary, additional HCQ therapy is effective
in patients with SLE in the maintenance phase.

References: Wakiya R, Kameda T, Nakashima S, Shimada H, Fahmy Mansour MM, Kato M, Miyagi T, Kadowaki N, Dobashi H.